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BACKGROUND
Tuberculous meningitis is often lethal. Early antituberculosis treatment and adjunctive 
treatment with glucocorticoids improve survival, but nearly one third of patients with 
the condition still die. We hypothesized that intensified antituberculosis treatment 
would enhance the killing of intracerebral Mycobacterium tuberculosis organisms and 
decrease the rate of death among patients.
METHODS
We performed a randomized, double-blind, placebo-controlled trial involving human 
immunodeficiency virus (HIV)–infected adults and HIV-uninfected adults with a clini-
cal diagnosis of tuberculous meningitis who were admitted to one of two Vietnamese 
hospitals. We compared a standard, 9-month antituberculosis regimen (which included 
10 mg of rifampin per kilogram of body weight per day) with an intensified regimen 
that included higher-dose rifampin (15 mg per kilogram per day) and levofloxacin 
(20 mg per kilogram per day) for the first 8 weeks of treatment. The primary outcome 
was death by 9 months after randomization.
RESULTS
A total of 817 patients (349 of whom were HIV-infected) were enrolled; 409 were ran-
domly assigned to receive the standard regimen, and 408 were assigned to receive inten-
sified treatment. During the 9 months of follow-up, 113 patients in the intensified-
treatment group and 114 patients in the standard-treatment group died (hazard ratio, 
0.94; 95% confidence interval, 0.73 to 1.22; P = 0.66). There was no evidence of a signifi-
cant differential effect of intensified treatment in the overall population or in any of the 
subgroups, with the possible exception of patients infected with isoniazid-resistant 
M. tuberculosis. There were also no significant differences in secondary outcomes between 
the treatment groups. The overall number of adverse events leading to treatment inter-
ruption did not differ significantly between the treatment groups (64 events in the 
standard-treatment group and 95 events in the intensified-treatment group, P = 0.08).
CONCLUSIONS
Intensified antituberculosis treatment was not associated with a higher rate of survival 
among patients with tuberculous meningitis than standard treatment. (Funded by the 
Wellcome Trust and the Li Ka Shing Foundation; Current Controlled Trials number, 
ISRCTN61649292.)
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Early treatment with antitubercu-losis chemotherapy and adjunctive treat-ment with glucocorticoids reduce the rate 
of death and disability from tuberculous menin-
gitis, but the disease still kills or disables almost 
half the patients with the condition.1,2 The cur-
rent guidelines recommend treatment with four 
antituberculosis drugs for at least the first 
2 months of therapy, followed by treatment with 
two drugs (rifampin and isoniazid) for an addi-
tional 7 to 10 months.3,4 However, these recom-
mendations are based on data from pulmonary 
tuberculosis and do not take into account the 
differential ability of antituberculosis drugs to 
penetrate the brain.
Rifampin is considered to be a critical drug 
in tuberculosis treatment, but concentrations 
of the drug in cerebrospinal f luid (CSF) are less 
than 30% of the concentration in plasma.5-7 In 
pulmonary tuberculosis, an increase in the oral 
dose of rifampin from 10 to 13 mg per kilogram 
of body weight had an acceptable side effect 
profile and led to a 65% increase in plasma con-
centrations of the drug.8 A recent randomized 
comparison of higher-dose intravenous rifampin 
(approximately 13 mg per kilogram per day) ver-
sus a standard oral dose (10 mg per kilogram 
per day) in 60 Indonesian adults with tuberculous 
meningitis showed that mortality among patients 
who received the higher intravenous dose was 
50% lower than that among patients who re-
ceived the standard dose.9
Fluoroquinolones are active antituberculosis 
agents with good penetration of the blood–brain 
barrier.10 For example, the concentration of levo-
floxacin in CSF reaches 70% of the concentra-
tion in plasma, and the drug has early bacteri-
cidal activity approaching that of isoniazid.10-12 
A randomized study involving Vietnamese adults 
with tuberculous meningitis suggested that the 
initial addition of levofloxacin to a standard four-
drug antituberculosis regimen improved the sur-
vival rate, especially among patients who were 
treated before the onset of coma.10 We therefore 
sought to test the hypothesis that intensified 
antituberculosis treatment — with higher-dose 
rifampin (15 mg per kilogram per day) and the 
addition of levofloxacin (20 mg per kilogram per 
day) for the first 8 weeks of treatment — would 
result in lower rates of death and disability from 
tuberculous meningitis than the rates with the 
currently recommended regimen.
Me thods
Study Population and Setting
We recruited study participants from two cen-
ters in Ho Chi Minh City, Vietnam: Pham Ngoc 
Thach Hospital for Tuberculosis and Lung Dis-
ease and the Hospital for Tropical Diseases. 
These 500-bed hospitals serve the local commu-
nity and act as tertiary referral centers for patients 
with severe tuberculosis (Pham Ngoc Thach 
Hospital) or infectious diseases (Hospital for 
Tropical Diseases) in southern Vietnam.
A full description of the methods has been 
published elsewhere13 and is provided in the 
protocol, available with the full text of this arti-
cle at NEJM.org. Adults (≥18 years of age) with 
a clinical diagnosis of tuberculous meningitis 
(at least 5 days of meningitis symptoms, nuchal 
rigidity, and CSF abnormalities) were eligible to 
enter the trial. Patients were subsequently classi-
fied as having definite, probable, or possible 
tuberculous meningitis or an alternative condi-
tion, in accordance with published diagnostic 
criteria14 (Table S1 in the Supplementary Appen-
dix, available at NEJM.org). Patients could not 
enter the trial if they had received more than 
7 days of antituberculosis drugs for the current 
infection; if they were known or suspected to be 
pregnant; if they had known or suspected hyper-
sensitivity to or unacceptable side effects from 
fluoroquinolones or rifampin; if multidrug-resis-
tant tuberculosis was known (on the basis of 
previous sputum drug susceptibility test results 
or Xpert MTB/RIF assay [Cepheid]) or suspected 
to be present; or if the plasma creatinine con-
centration was more than three times the upper 
limit of the normal range (for males, >360 μmol 
per liter [4.07 mg per deciliter], and for females, 
>300 μmol per liter [3.39 mg per deciliter]), if 
the plasma bilirubin concentration was more 
than 2.5 times the upper limit of the normal 
range (total bilirubin >42.5 mmol per liter), or if 
the plasma aspartate or alanine aminotransfer-
ase level was more than five times the upper 
limit of the normal range (>185 U per liter or 
>200 U per liter, respectively).
Study Oversight
Written informed consent to participate in the 
study was obtained from all patients or from 
their relatives if the patient could not provide 
consent. The trial was approved by the Oxford 
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Tropical Research Ethics Committee, the institu-
tional review board at the Hospital for Tropical 
Diseases and at Pham Ngoc Thach Hospital, and 
the ethics committee of the Ministry of Health, 
Vietnam. An independent data and safety moni-
toring board reviewed the data after 6 months, 
1 year, 2 years, and 3 years. The Xpert MTB/RIF 
assays used in the study were purchased. The 
rifampin and its matching placebo, as well as 
some of the levofloxacin, was purchased from 
Mekophar and Sanofi, respectively. Some of the 
levofloxacin and all of the levofloxacin matching 
placebo were donated by Sanofi. Neither Meko-
phar nor Sanofi played a part in the design, 
implementation, or analysis of the study, includ-
ing manuscript preparation, or in the decision to 
submit the results for publication. All the authors 
vouch for the accuracy and completeness of the 
data and for the fidelity of this report to the 
study protocol.
Laboratory Investigations
CSF specimens were stained and cultured with 
the use of standard methods for pyogenic bacte-
ria, fungi, and mycobacteria and were tested with 
an Xpert MTB/RIF assay. Isolates of Mycobacterium 
tuberculosis were tested for susceptibility to iso-
niazid, rifampin, ethambutol, and streptomycin 
by means of the mycobacterial growth indicator 
tube method.15 All patients were tested for anti-
bodies to human immunodeficiency virus (HIV) 
and hepatitis C and for the presence of hepatitis 
B surface antigen. CD4 cell counts were measured 
for all HIV-infected adults as soon as possible 
after randomization.
Study Treatment
All patients received standard oral antituberculo-
sis treatment, which consisted of isoniazid (5 mg 
per kilogram per day; maximum, 300 mg per 
day), rifampin (10 mg per kilogram per day), 
pyrazinamide (25 mg per kilogram per day; 
maximum, 2 g per day), and ethambutol (20 mg 
per kilogram per day; maximum, 1.2 g per day) 
for 3 months, followed by rifampin and isoniazid 
at the same doses for an additional 6 months. 
Patients who had previously received treatment 
for tuberculosis also received streptomycin (20 mg 
per kilogram per day; maximum, 1 g per day) for 
the first 3 months. All patients received adjunc-
tive treatment with dexamethasone for the first 
6 to 8 weeks of treatment, as described previ-
ously.16 Intensified treatment consisted of the 
standard 9-month regimen with the addition for 
the first 8 weeks of treatment of a weight-based 
dose of rifampin (5 mg per kilogram per day, to 
achieve a total dose of 15 mg per kilogram per 
day) and of levofloxacin (20 mg per kilogram per 
day) (Table S2 in the Supplementary Appendix). 
Adherence to treatment was ensured with the 
use of supervised drug intake for inpatients, 
encouraged by detailed instructions at discharge, 
and measured by pill counts at the monthly fol-
low-up visits. For patients infected with M. tuber-
culosis that was resistant to rifampin, isoniazid, 
or both, treatment was adjusted in accordance 
with local practices and the susceptibility of the 
organism.
HIV-infected patients received antiretroviral 
therapy in accordance with Vietnamese guide-
lines. Antiretroviral therapy that was started be-
fore enrollment was continued unless it was 
contraindicated for use with rifampin. If the 
antiretroviral therapy regimen that the patient 
was receiving at the time of enrollment included 
nevirapine, that drug was switched to efavirenz. 
For patients who had not previously received 
antiretroviral therapy, the therapy was started 
after 8 weeks of antituberculosis therapy.17 Co-
trimoxazole prophylaxis (960 mg per day) was 
given to all patients who had CD4 cell counts 
below 200 per cubic millimeter.
Randomization and Concealment  
of Study-Group Assignments
Patients were stratified at study entry according 
to site, HIV infection status, and the modified 
British Medical Research Council criteria (MRC 
grade).18 MRC grade 1 indicates a Glasgow coma 
score of 15 (on a scale of 3 to 15, with lower 
scores indicating reduced levels of conscious-
ness) with no neurologic signs, grade 2 a score 
of 11 to 14 (or a score of 15 with focal neuro-
logic signs), and grade 3 a score of 10 or lower. 
Patients were randomly assigned in a 1:1 ratio to 
receive either standard or intensive antituberculo-
sis treatment according to a computer-generated 
randomization list, with randomization in vari-
able block sizes of 4 and 6.
The study pharmacist prepared visually 
matched pills in identical, sequentially num-
bered treatment packs according to the random-
ization list for dispensation in sequential order 
as patients were recruited. All the participants, 
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enrolling physicians, and investigators remained 
unaware of the treatment assignments until the 
last patient completed follow-up. The attending 
physicians were responsible for enrolling the 
participants and for ensuring that the study 
drug was given from the correct treatment pack. 
Daily monitoring of all inpatients by one of the 
investigators ensured uniform management be-
tween the study sites and accurate recording of 
clinical data in individual study notes.
Outcome Assessments
The condition of the patients was reviewed daily 
until discharge from the hospital for assessment 
of clinical progress and neurologic and drug-
related adverse events. After discharge, monthly 
visits were scheduled for clinical evaluation and 
laboratory monitoring until the completion of 
treatment at 9 months.
The primary outcome was death by 9 months 
after randomization. The secondary outcomes 
included neurologic disability at 9 months, time 
to the first new neurologic event or death, and 
serious adverse events. The disability outcome was 
assessed with the use of the “simple questions” 
score (based on the answers to two yes-or-no 
questions regarding the patient’s dependency on 
others in daily activities and whether the illness 
has left the patient with any other problems) and 
the modified Rankin score (a disability score 
that ranges from 0 [no symptoms] to 5 [totally 
dependent on others]) and was classified as 
“good outcome,” “intermediate outcome,” “severe 
disability,” or “death,” as described previous-
ly.16,17,19 Patients were assessed at 2, 6, and 
9 months after randomization; the worst score 
from either questionnaire was taken as the out-
come. If the 9-month disability assessment was 
missing, the previous assessment was used in-
stead. New neurologic events were defined as 
the occurrence of any of the following: cerebel-
lar symptoms; monoplegia, hemiplegia, paraple-
gia, or tetraplegia; seizures; cranial nerve palsy; 
or a decrease in Glasgow coma score of 2 or 
more points for 2 or more days from the highest 
previously recorded score.
Statistical Analysis
We calculated that with a sample size of at least 
750 patients, including a minimum of 350 HIV-
infected patients, the trial would have 80% power 
to detect a 10-percentage-point lower 9-month 
risk of death among patients receiving the inten-
sified treatment than among those receiving the 
standard treatment (30% vs. 40%, corresponding 
to a target hazard ratio of 0.7) in the overall 
population and a 15-percentage-point lower risk 
of death in the subgroup of HIV-infected patients 
(50% vs. 65%), at a two-sided 5% significance 
level.
The statistical analysis followed the protocol13 
and the statistical analysis plan (see the Supple-
mentary Appendix). The primary outcome was 
analyzed in all patients and in prespecified 
subgroups, with the analysis based on the Cox 
proportional-hazards model with stratification 
according to HIV infection status and MRC grade. 
The ordinal disability score was compared be-
tween the two study groups with a proportional-
odds logistic-regression model with adjustment 
for HIV infection status and MRC grade. Second-
ary time-to-event outcomes were analyzed in the 
same way as the primary outcome. Additional 
prespecified multivariable Cox regression analy-
ses and analyses of the disability score were 
based on multiple imputation of missing covari-
ates and disability outcomes, as detailed in the 
statistical analysis plan.
The primary analysis population was the inten-
tion-to-treat population, which included all pa-
tients who underwent randomization. The analy-
sis of the primary outcome was repeated in the 
per-protocol population, which did not include 
patients with unlikely tuberculous meningitis or 
an alternative diagnosis according to the diagnos-
tic criteria,14 patients with multidrug-resistant 
infections, or patients who received less than 
50 days of treatment with the study drug for 
reasons other than death. All statistical analyses 
were performed with the statistical software R, 
version 3.1.2.20
R esult s
Study Population
From April 18, 2011, through June 18, 2014, a 
total of 817 adult patients were randomly assigned 
to receive standard antituberculosis treatment plus 
either placebo (409 patients; standard-treatment 
group) or additional rifampin and levofloxacin 
(408 patients; intensified-treatment group). A total 
of 53 patients (28 in the standard-treatment group 
and 25 in the intensified-treatment group) did not 
complete follow-up for reasons other than death.
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A total of 121 patients (59 in the standard-
treatment group and 62 in the intensified-treat-
ment group) were not included in the per-protocol 
population. A condition other than tuberculous 
meningitis was diagnosed in 14 patients (5 in the 
standard-treatment group and 9 in the intensi-
fied-treatment group), and 8 patients (3 in the 
standard-treatment group and 5 in the intensi-
fied-treatment group) were deemed unlikely to 
have tuberculous meningitis. A total of 103 pa-
tients received less than 50 days of treatment 
with the study regimens for reasons other than 
death, and 15 of these patients were determined 
to have multidrug-resistant tuberculous meningi-
tis (Fig. 1). We assessed adherence to the 8-week 
intervention, and 4.0% of the participants (33 of 
817, 19 in the standard-treatment group and 14 
in the intensified-treatment group) were judged 
to be nonadherent (<100% medication doses 
received).
Baseline Characteristics
The characteristics of the patients at baseline 
were balanced between the two treatment groups, 
with the exception of sodium concentrations in 
plasma (lower in the intensified-treatment group), 
the frequency of a previous episode of tubercu-
losis (higher in the intensified-treatment group), 
Figure 1. Screening and Randomization.
Among the patients in the intention-to-treat population, in the standard-treatment group, 22 were lost to follow-up, 
5 withdrew from the study, 1 went home to die but could not be contacted, 1 died before the study treatment was 
given, and 6 had their treatment assignment revealed; in the intensified-treatment group, 21 were lost to follow-up, 
2 withdrew from the study, 2 withdrew before the study treatment was given, and 3 had their treatment assignment 
revealed. Among the patients who were confirmed to have a condition other than tuberculous meningitis, in the 
standard-treatment group, four had cryptococcal meningitis and one had an intracranial tumor; in the intensified-
treatment group, seven had cryptococcal meningitis, one had encephalitis caused by herpes simplex virus, and one 
had eosinophilic meningitis.
817 Underwent randomization
1207 Patients were assessed for eligibility
390 Were excluded (some with more
than one reason)
163 Did not meet inclusion criteria
167 Declined to participate
62 Had other reasons
409 Were assigned to standard treatment and
included in the intention-to-treat analysis
408 Were assigned to intensified treatment and
included in the intention-to-treat analysis
62 Were excluded (some with
more than one reason)
52 Had <50 days of study
treatment
9 Were confirmed to have
a different condition
5 Were unlikely to have
tuberculous meningitis
8 Had multidrug-resistant
tuberculous meningitis
59 Were excluded (some with
more than one reason)
51 Had <50 days of study
treatment
5 Were confirmed to have
a different condition
3 Were unlikely to have
tuberculous meningitis
7 Had multidrug-resistant
tuberculous meningitis
350 Were included in the per-protocol
analysis
346 Were included in the per-protocol
analysis
The New England Journal of Medicine 
Downloaded from nejm.org at LIVERPOOL SCHOOL OF TROPICAL MEDICINE on June 30, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 374;2 nejm.org January 14, 2016 129
Antituberculosis Ther apy in Tuberculous Meningitis
total white-cell count in the CSF (higher in the 
intensified-treatment group), and lymphocyte 
percentage in the CSF (lower in the intensified-
treatment group) (Table 1, and Table S3 in the 
Supplementary Appendix). A total of 68.5% of 
the patients were men, the median age of the 
patients was 35 years, and the median duration 
of illness was 15 days. A majority of the patients 
had mild-to-moderate illness; only 17.4% had 
MRC grade 3 illness at enrollment. A total of 
42.7% of patients were infected with HIV. Using 
the published diagnostic criteria,14 we defined 
49.8% of the patients as having definite tubercu-
lous meningitis, 26.2% as having probable tu-
berculous meningitis, and 21.3% as having pos-
sible tuberculous meningitis. Among the patients 
with culture-confirmed disease, 26.7% had iso-
niazid-resistant infection, and 4.7% had multi-
Characteristic
Standard Regimen 
(N = 409)
Intensified Regimen 
(N = 408)
All Patients 
(N = 817)
Male sex — no. (%) 278 (68.0) 282 (69.1) 560 (68.5)
Median age (IQR) — yr 35 (30–47) 35 (29–45) 35 (29–46)
MRC grade — no. (%)†
1 160 (39.1) 158 (38.7) 318 (38.9)
2 178 (43.5) 179 (43.9) 357 (43.7)
3 71 (17.4) 71 (17.4) 142 (17.4)
HIV-infected — no. (%) 174 (42.5) 175 (42.9) 349 (42.7)
Median CD4 count (IQR) — cells/mm3‡ 38 (15–82) 38 (14–113) 38 (14–101)
Diagnostic category — no. (%)§
Definite tuberculous meningitis 201 (49.1) 206 (50.5) 407 (49.8)
Probable tuberculous meningitis 109 (26.7) 105 (25.7) 214 (26.2)
Possible tuberculous meningitis 91 (22.2) 83 (20.3) 174 (21.3)
Unlikely to be tuberculous meningitis 3 (0.7) 5 (1.2) 8 (1.0)
Confirmed other condition 5 (1.2) 9 (2.2) 14 (1.7)
Resistance category
Drug-susceptibility test results available — no. 156 166 322
No isoniazid or rifampin resistance — no. 
(%)¶
107 (68.6) 113 (68.1) 220 (68.3)
Isoniazid monoresistance — no. (%) 41 (26.3) 45 (27.1) 86 (26.7)
Rifampin monoresistance — no. (%) 1 (0.6) 0 1 (0.3)
Multidrug resistance — no. (%) 7 (4.5) 8 (4.8) 15 (4.7)
*  No characteristic differed significantly between the study groups (P≤0.05 at baseline according to Fisher’s exact test  
for categorical data or the Wilcoxon rank-sum test for continuous data), with the exception of sodium concentration 
(P = 0.004), frequency of a previous episode of tuberculosis (P = 0.045), total white-cell count in the cerebrospinal fluid 
(P = 0.006), and lymphocyte percentage in the cerebrospinal fluid (P = 0.01); the complete list of baseline characteristics 
is provided in Table S3 in the Supplementary Appendix. IQR denotes interquartile range.
†  Medical Research Council (MRC) grade 1 indicates a Glasgow coma score of 15 (on a scale of 3 to 15, with lower scores 
indicating reduced levels of consciousness) with no neurologic signs, grade 2 a score of 11 to 14 (or 15 with focal neu-
rologic signs), and grade 3 a score of 10 or less.
‡  CD4 cell counts were assessed only in HIV-infected patients. Data were missing for 30 patients in the standard-treat-
ment group and for 25 patients in the intensified-treatment group.
§  Diagnostic categories were assigned according to the consensus case definition.14 Patients whose condition was unlike-
ly to be tuberculous meningitis had a score of less than 6 on the scale based on the consensus case definition (maxi-
mum score, 20) (see Table S1 in the Supplementary Appendix). Confirmation of another condition was made only on 
the basis of microbiologic evidence.
¶  Isoniazid monoresistance is defined as resistance to isoniazid but not to rifampin. Multidrug resistance is defined as 
resistance to at least isoniazid and rifampin. In all categories, resistance to other drugs may be present.
Table 1. Characteristics of the Patients at Enrollment.*
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drug-resistant infection. The baseline clinical 
characteristics of the patients according to MRC 
illness severity grade are provided in Table S4 in 
the Supplementary Appendix.
Primary Outcome
During 9 months of follow-up, 113 patients in 
the intensified-treatment group and 114 patients 
in the standard-treatment group died (hazard 
ratio, 0.94; 95% confidence interval [CI], 0.73 to 
1.22; P = 0.66) (Fig. 2). There was no evidence of 
a differential effect of intensified treatment in the 
overall population or in any of the prespecified 
subgroups, although there was a suggestion of 
benefit of intensified treatment for patients with 
isoniazid-resistant infections (P = 0.06) (Table 2). 
The probability of overall survival according to 
treatment group in the per-protocol population 
and MRC-grade groups is shown in Figures S1 
and S2 in the Supplementary Appendix.
A Cox regression analysis (Table S5 in the 
Supplementary Appendix) identified the follow-
ing factors as predictors of poor survival: more 
severe neurologic compromise at treatment ini-
tiation, as indicated by a higher MRC grade 
(hazard ratio for grade 2 vs. grade 1, 2.41; 95% 
CI, 1.70 to 3.42; hazard ratio for grade 3 vs. 
grade 1, 6.31; 95% CI, 4.36 to 9.12); HIV infec-
tion (hazard ratio, 2.53; 95% CI, 1.90 to 3.36); 
and multidrug-resistant or rifampin-resistant in-
fection (hazard ratio, 4.72; 95% CI 2.41 to 9.24) 
or infection with unknown drug resistance (haz-
ard ratio as compared with no isoniazid or ri-
fampin resistance, 1.76; 95% CI, 1.27 to 2.45). In 
HIV-infected patients, a higher CD4 cell count 
was associated with reduced mortality (hazard 
ratio per increase of 100 cells per cubic milli-
meter, 0.62; 95% CI, 0.44 to 0.87).
Secondary Outcomes and Adverse Events
There was no evidence of a differential effect of 
intensified treatment on any of the prespecified 
secondary outcomes (Table S6 in the Supplemen-
tary Appendix). Overall, there was no significant 
difference between the treatment groups with 
regard to clinical adverse events, apart from a 
higher frequency of seizures in the intensified-
treatment group than in the standard-therapy 
group (23 vs. 11 patients, P = 0.04), as well as a 
higher frequency of vision impairment in the 
intensified-treatment group (14 vs. 4, P = 0.02) 
(Table 3). Signs of drug allergy were more fre-
quent in the intensified-treatment group than in 
the standard-therapy group (occurring in 30 pa-
tients vs. 17 patients); however, this difference 
did not reach significance (P = 0.052). The differ-
ence between the study groups in the number of 
adverse events leading to interruptions in anti-
tuberculosis treatment also did not reach sig-
nificance (64 events in the standard-treatment 
group vs. 95 in the intensified-treatment group, 
P = 0.08) (Table S7 in the Supplementary Appen-
dix). There were more interruptions due to jaun-
dice in the intensified-treatment group than in the 
standard-treatment group (in 19 vs. 7 patients, 
P = 0.02). Additional laboratory abnormalities are 
listed in Table S5 in the Supplementary Appen-
dix. There were significantly more patients with 
grade 3 or grade 4 increases in bilirubin level 
in the intensified-treatment group than in the 
standard-treatment group (49 vs. 31, P = 0.04), as 
well as significantly more patients with grade 3 
or 4 hyponatremia (112 vs. 81, P = 0.01) (Table S8 
in the Supplementary Appendix). The median du-
ration of the initial hospitalization was 31 days 
in the intensified-treatment group and 30 days 
in the standard-treatment group. A total of 11 
patients (4 in the standard-treatment group and 
7 in the intensified-treatment group) had a pro-
longation of the corrected QT interval above the 
critical threshold of 500 msec (calculated with 
the use of the Framingham formula) at any time 
between baseline and 4 weeks of treatment.
Discussion
In this pragmatic, randomized, double-blind, 
placebo-controlled trial involving adults with 
tuberculous meningitis, intensified antitubercu-
losis treatment was not associated with a higher 
rate of survival than the rate with standard treat-
ment. The results contradict the findings of 
previous studies that suggested that an increase 
in rifampin dose9 and the addition of a f luoro-
quinolone to the standard regimen10 may im-
prove the outcome in patients with tuberculous 
meningitis.
A limitation of our study was that we tested a 
regimen rather than the contribution of individ-
ual drugs. A factorial design may have enabled 
the latter but would have led to the need for a 
prohibitively large sample size.21 However, our 
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negative findings suggest that neither a higher 
dose of rifampin nor a higher dose of levofloxa-
cin improves tuberculous meningitis treatment.
There are a number of possible explanations 
for our results. It is possible that the oral ri-
fampin dose used in our study (15 mg per kilo-
gram per day) did not increase the intracerebral 
drug concentrations sufficiently to enhance bac-
terial killing. Recent data suggest that much 
higher doses of rifampin (up to 35 mg per kilo-
gram per day) may have an acceptable side-effect 
profile and may be necessary to significantly 
increase the killing of M. tuberculosis in pulmo-
nary tuberculosis.22 Furthermore, oral adminis-
tration probably results in substantially lower 
rifampin concentrations in plasma than does 
intravenous administration of equivalent doses.23 
Some reports have suggested that the relative 
benefit of rifampin in the treatment of tubercu-
lous meningitis may be modest in the presence 
of effective mycobacterial killing by isoniazid.24 
The main role of rifampin in the treatment of 
pulmonary tuberculosis is probably to shorten 
the treatment duration rather than to enhance 
early mycobacterial killing.25,26 In contrast, fluo-
roquinolones have enhanced the early steriliza-
tion of sputum but have not allowed the duration 
of therapy to be shortened, because of unaccept-
able increases in disease relapses.27-29 Previous 
studies have shown that fluoroquinolones either 
have no effect on the outcome of tuberculous 
meningitis9 or confer a possible benefit in pa-
tients with mild disease.10 A pharmacokinetic 
and pharmacodynamic analysis involving the pa-
tients recruited for our trial may help address 
these possibilities.
An intensified antituberculosis regimen may, 
however, benefit patients infected with isoniazid-
resistant M. tuberculosis. The way in which this 
finding should influence clinical practice is un-
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Figure 2. Kaplan–Meier Curves for Overall Survival 
 According to Treatment Group and HIV Infection Status.
In accordance with the statistical analysis plan, all deaths 
in the database were included in the final analysis; this 
included two deaths on days 274 and 275. Because the 
9-month follow-up visit was on days 270 through 272 
for most patients, the numbers of patients at risk on 
days 274 and 275 were low, which accounts for the 
sharp decrease in the Kaplan–Meier curves at the end  
of the study period.
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certain, given that the detection of isoniazid re-
sistance usually requires bacterial culture and 
often takes many weeks. The development of 
rapid molecular tests that can reliably detect 
isoniazid resistance in cerebrospinal fluid may 
aid in early diagnosis and treatment adjustments. 
However, empirical intensification of treatment 
regimens may be warranted in patients who are 
at high risk for isoniazid-resistant infection or in 
settings with a high prevalence of isoniazid-re-
sistant bacteria.
The overall mortality in our population was 
lower than that anticipated on the basis of previ-
ous reports. This may be due to a combination 
of earlier diagnosis (38.9% of patients had MRC 
grade 1 disease at randomization), increased 
availability of second-line drugs for drug-resis-
tant infections, and improved management of 
Subgroup
Standard Regimen 
(N = 409)
Intensified Regimen 
(N = 408)
Hazard Ratio 
(95% CI) P Value
P Value for 
Heterogeneity*
no. of deaths/total no. of patients
Intention-to-treat population 114/409 113/408 0.94 (0.73–1.22) 0.66
Per-protocol population 94/350 93/346 0.91 (0.68–1.21) 0.52
MRC grade 0.69
1 25/160 21/158 0.82 (0.46–1.46) 0.49
2 50/178 52/179 1.07 (0.72–1.57) 0.74
3 39/71 40/71 0.87 (0.56–1.36) 0.55
HIV infection status 0.74
Uninfected 46/235 45/233 1.00 (0.66–1.51) 1.00
Infected† 68/174 68/175 0.91 (0.65–1.27) 0.57
Previous tuberculosis 0.82
No 89/347 78/324 0.91 (0.67–1.23) 0.53
Yes 25/62 35/84 0.99 (0.59–1.67) 0.97
Receiving antituberculosis treatment 
at enrollment‡
0.02
No 36/150 49/149 1.38 (0.89–2.12) 0.15
Yes 78/259 64/259 0.74 (0.53–1.03) 0.07
Diagnostic category§ 0.93
Definite tuberculous meningitis 56/201 55/206 0.90 (0.62–1.31) 0.57
Probable tuberculous meningitis 30/109 33/105 1.10 (0.66–1.83) 0.71
Possible tuberculous meningitis 28/91 25/83 0.94 (0.54–1.63) 0.82
Resistance category 0.04
No or other resistance 22/107 30/113 1.54 (0.88–2.71) 0.13
Isoniazid resistance 16/41 11/45 0.45 (0.20–1.02) 0.06
Rifampin or multidrug resistance 6/8 5/8 0.63 (0.15–2.69) 0.53
*  Heterogeneity was tested with a likelihood ratio test for an interaction term between the subgroup variable and the randomly assigned treat-
ment group. As prespecified, the Cox regression was stratified according to MRC grade and HIV infection status.
†  Among the patients who were not receiving antiretroviral therapy at enrollment, 49 of 114 patients (43%) in the intensified-treatment group 
died (30 of them in the first 8 weeks), and 44 of 115 patients (38%) in the standard-treatment group died (29 of them in the first 8 weeks). 
Among the patients who were receiving antiretroviral therapy at enrollment, 19 of 61 patients (31%) in the intensified-treatment group died 
(9 of them in the first 8 weeks), and 24 of 59 patients (41%) in the standard-treatment group died (18 of them in the first 8 weeks).
‡  Patients were not eligible to enter the trial if they had received more than 7 days of antituberculosis treatment before enrollment. The median 
duration of antituberculosis treatment was 4 days (interquartile range, 2 to 5).
§  A total of 22 patients with unlikely tuberculous meningitis or a confirmed other condition were not included.
Table 2. Survival during the 9-Month Study Period.
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HIV infection. Although the results of our study 
do not support a change in the currently recom-
mended treatment regimens for tuberculous 
meningitis, enhanced antituberculosis treatment 
with higher doses of first-line antituberculosis 
drugs, including intravenous rifampin, or the 
newer antituberculosis drugs bedaquiline and 
delamanid, still require investigation. In the 
Adverse Event
Standard Regimen 
(N = 409)
Intensified Regimen 
(N = 408) P Value†
no. of patients (%)
Any event 229 (56.0) 240 (58.8) 0.44
Neurologic event 155 (37.9) 173 (42.4) 0.20
Deterioration of consciousness 89 (21.8) 90 (22.1) 0.93
Headache 30 (7.3) 36 (8.8) 0.44
Hemiplegia 21 (5.1) 31 (7.6) 0.16
Paraplegia 9 (2.2) 10 (2.5) 0.82
Urinary retention 12 (2.9) 10 (2.5) 0.83
Cranial-nerve palsies 11 (2.7) 13 (3.2) 0.69
Seizures 11 (2.7) 23 (5.6) 0.04
Vision impairment 4 (1.0) 14 (3.4) 0.02
Hepatotoxicity 28 (6.8) 17 (4.2) 0.12
Jaundice 17 (4.2) 29 (7.1) 0.07
Respiratory event 18 (4.4) 18 (4.4) 1.00
Event requiring mechanical ventilation 10 (2.4) 14 (3.4) 0.42
Signs of drug allergy 17 (4.2) 30 (7.4) 0.052
Cardiologic events 14 (3.4) 13 (3.2) 1.00
Diarrhea 7 (1.7) 5 (1.2) 0.77
Vomiting 13 (3.2) 18 (4.4) 0.37
Severe abdominal pain 12 (2.9) 5 (1.2) 0.14
Fever 8 (2.0) 9 (2.2) 0.81
Hemorrhage or anemia 16 (3.9) 17 (4.2) 0.86
Other hematologic event 4 (1.0) 3 (0.7) 1.00
New AIDS-defining illness 6 (1.5) 10 (2.5) 0.33
Gastrointestinal bleeding 3 (0.7) 1 (0.2) 0.62
Other gastrointestinal symptoms 3 (0.7) 9 (2.2) 0.09
Renal event 2 (0.5) 3 (0.7) 0.69
Urinary symptoms 0 1 (0.2) 0.50
Dermatologic symptoms 5 (1.2) 6 (1.5) 0.77
Peripheral edema 0 4 (1.0) 0.06
Musculoskeletal symptoms 3 (0.7) 3 (0.7) 1.00
Exhaustion 2 (0.5) 4 (1.0) 0.45
Other 14 (3.4) 12 (2.9) 0.84
*  In total, 446 adverse events occurred in the standard-treatment group and 534 adverse events occurred in the intensi-
fied-treatment group (P = 0.09, by the Wilcoxon rank-sum test). AIDS denotes acquired immunodeficiency syndrome.
†  P values were calculated with the use of Fisher’s exact test.
Table 3. Clinical Grade 3 and 4 Adverse Events.*
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meantime, the key determinants of survival from 
this dangerous infection are earlier diagnosis 
and treatment.
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